IMMUNOTHERAPY OF SOLID TOMOR BY INTRATUMORAL INFUSION OF LYMPHOKINE‐ACTIVATED KILLER CELLS

Fifty million lymphokine‐activated killer (LAK) cells were infused into rat T9 gliosarcoma tumors for 1 hr at an infusion rate of 0.1 ml/hr. Cultured normal spleen cells were infused into similar tumors as a control. The LAK cell‐treated tumors began to regress at approximately 3 weeks after infusion and disappeared by 6 weeks, while the cultured normal spleen cell‐treated tumors grew progressively. Immunohistochemical analysis demonstrated prominent infiltration of cytotoxic/suppressor T cells in the LAK cell‐treated tumors, while few lymphocytes were recognized in the control tumors. These data suggested that LAK cells infused intratumorally might be capable of mediating tumor regression by inducing host immunity against the tumor.

[1]  F. Bach,et al.  Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. , 1987, Journal of immunology.

[2]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[3]  M. Papa,et al.  Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Rosenberg,et al.  Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. , 1986, Cancer research.

[5]  S. Rosenberg,et al.  Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. , 1985, Journal of immunology.

[6]  T. Diamantstein,et al.  Functional analysis of mononuclear cells infiltrating into tumors. II. Differential ability of mononuclear cells obtained from various tissues to produce helper factors that are involved in the generation of cytotoxic cells. , 1985, Journal of immunology.

[7]  S. Rosenberg.  Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. , 1985, Journal of the National Cancer Institute.

[8]  T. Uede,et al.  A soluble factor distinct from interleukin 2 is involved in the generation and differentiation of cytotoxic T cells. , 1985, Japanese journal of cancer research : Gann.

[9]  S. Rosenberg,et al.  Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. , 1985, Cancer research.

[10]  R. Evans,et al.  Amplification of immune T lymphocyte function in situ: the identification of active components of the immunologic network during tumor rejection. , 1985, Journal of immunology.

[11]  S. Rosenberg,et al.  Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. , 1985, Journal of immunology.

[12]  S. Rosenberg,et al.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. , 1985, Journal of immunology.

[13]  T. Uede,et al.  Functional analysis of mononuclear cells infiltrating into tumors: differential cytotoxicity of mononuclear cells from tumors of immune and nonimmune rats. , 1985, Journal of immunology.

[14]  S. Rosenberg,et al.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. , 1984, Science.

[15]  T. Takami,et al.  Lymphoid cell subpopulations infiltrating into autologous rat tumors undergoing rejection. , 1984, Cancer research.

[16]  S. Rosenberg,et al.  Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. , 1984, Cancer research.

[17]  T. Takami,et al.  Rat T lymphocyte antigens comparable with mouse Lyt-1 and Lyt-2,3 antigenic systems: characterization by monoclonal antibodies. , 1984, Journal of immunology.

[18]  S. Rosenberg,et al.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes , 1982, The Journal of experimental medicine.

[19]  P. Greenberg,et al.  Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia. , 1980, Cancer research.

[20]  D. Mathisen,et al.  The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. , 1980, Journal of immunology.

[21]  R. North,et al.  T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor , 1980, The Journal of experimental medicine.

[22]  Y. Ishii,et al.  CELL‐MEDIATED IMMUNITY INVOLVED IN AUTOCHTHONOUS TUMOR REJECTION IN RATS * , 1976, Annals of the New York Academy of Sciences.

[23]  H. Oettgen,et al.  Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors , 1972, International journal of cancer.

[24]  W. Sweet,et al.  Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. , 1971, Journal of neurosurgery.